BioInvent receives IND approval for Phase I/IIa trial of anti-TNFR2 antibody BI-1808

Corporate Breaking News

Home : BioInvent receives IND approval for Phase I/IIa trial of anti-TNFR2 antibody BI-1808

Apr 07 2021	BioInvent receives IND approval for Phase I/IIa trial of anti-TNFR2 antibody BI-1808
LUND, Sweden, April 7, 2021 /PRNewswire/ -- BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) for the Phase I/IIa clinical study of the immuno-modulatory...


Source:https://www.prnewswire.com:443/news-releases/bioinvent-receives-ind-approval-for-phase-iiia-trial-of-anti-tnfr2-antibody-bi-1808-301263794.html

Related News
» SGS leads the way with new comprehensive testing protocol for footwear packaging » Automotive Touch Screen Control Systems Market to reach 22.57 Million Units and Record a CAGR of Almost 7% \|Technavio